Abstract
Introduction: Genetic polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never‐smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of genetic polymorphisms in the BER and NER (base excision repair and nucleotide excision repair, respectively) DNA repair pathways on survival and toxicity in never‐smoker LC patients in a multicentric study performed in northwest-Spain (LCRINS).
Material-methods:: Between 2011-2019 all LC cases in never smokers from 11 hospitals were recruited. Survival was analyzed using Cox Regression. Analysis of each specific type of toxicity was performed with Chi-square test.
Results: 356 never smokers were included (79% women, 83% adenocarcinoma and 65% stage IV). Survival at 3 and 5 years from diagnosis was not associated with genetic polymorphisms, except in the subgroup of patients who received radiotherapy or chemo‐radiotherapy, and presented with ERCC1-rs3212986 polymorphism. There was greater toxicity in those presenting OGG1-rs1052133(CG) and ERCC1-rs11615 polymorphisms among patients treated with radiotherapy or chemo‐radiotherapy, respectively.
Conclusions: Polymorphisms in the BER and NER pathways do not seem to play a relevant role in survival and response to treatment among never-smoker LC patients. Further studies are called for to elucidate the mechanisms whereby genetic polymorphisms can influence toxicity or survival among never-smoker LC patients.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2300.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
